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ABSTRACT
Objective To assess the efficacy of vaginal progesterone
for the prevention of preterm birth and neonatal
morbidity and mortality in asymptomatic women with
a twin gestation and a sonographic short cervix (cervical
length ≤ 25 mm) in the mid-trimester.
Methods This was an updated systematic review and
meta-analysis of individual patient data (IPD) from
randomized controlled trials comparing vaginal pro-
gesterone with placebo/no treatment in women with a
twin gestation and a mid-trimester sonographic cervi-
cal length ≤ 25 mm. MEDLINE, EMBASE, POPLINE,
CINAHL and LILACS (all from inception to 31 Decem-
ber 2016), the Cochrane Central Register of Controlled
Trials, Research Registers of ongoing trials, Google
Scholar, conference proceedings and reference lists of
identified studies were searched. The primary outcome
measure was preterm birth < 33 weeks’ gestation. Two
reviewers independently selected studies, assessed the risk
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of bias and extracted the data. Pooled relative risks (RRs)
with 95% confidence intervals (CI) were calculated.
Results IPD were available for 303 women (159
assigned to vaginal progesterone and 144 assigned
to placebo/no treatment) and their 606 fetuses/infants
from six randomized controlled trials. One study,
which included women with a cervical length between
20 and 25 mm, provided 74% of the total sample
size of the IPD meta-analysis. Vaginal progesterone,
compared with placebo/no treatment, was associated
with a statistically significant reduction in the risk
of preterm birth < 33 weeks’ gestation (31.4% vs
43.1%; RR, 0.69 (95% CI, 0.51–0.93); moderate-quality
evidence). Moreover, vaginal progesterone administration
was associated with a significant decrease in the risk of
preterm birth < 35, < 34, < 32 and< 30 weeks’ gestation
(RRs ranging from 0.47 to 0.83), neonatal death (RR,
0.53 (95% CI, 0.35–0.81)), respiratory distress syndrome
(RR, 0.70 (95% CI, 0.56–0.89)), composite neonatal
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morbidity and mortality (RR, 0.61 (95% CI, 0.34–0.98)),
use of mechanical ventilation (RR, 0.54 (95% CI,
0.36–0.81)) and birth weight< 1500 g (RR, 0.53 (95%
CI, 0.35–0.80)) (all moderate-quality evidence). There
were no significant differences in neurodevelopmental
outcomes at 4–5 years of age between the vaginal
progesterone and placebo groups.
Conclusion Administration of vaginal progesterone to
asymptomatic women with a twin gestation and a
sonographic short cervix in the mid-trimester reduces the
risk of preterm birth occurring at < 30 to< 35 gestational
weeks, neonatal mortality and some measures of neonatal
morbidity, without any demonstrable deleterious effects
on childhood neurodevelopment. Published 2017. This
article is a U.S. Government work and is in the
public domain in the USA. Ultrasound in Obstetrics
& Gynecology published by John Wiley & Sons Ltd
on behalf of the International Society of Ultrasound in
Obstetrics and Gynecology.
INTRODUCTION
Twin births have become more prevalent in developed
countries over the last decades1–3. In 2014, the twin birth
rate in the USA was 33.9 per 1000 live births, the highest
rate ever recorded4. Twin gestations are at increased risk
of maternal, perinatal and infant morbidity and mortality,
as well as long-term neurodevelopmental disability5–13.
Moreover, twin gestations also have a significant impact
on healthcare costs and quality of life for both the parents
and the children7,14,15.
Preterm birth is the most important factor determining
neonatal morbidity and mortality among twins. The
risk of preterm birth < 37 and< 32 weeks’ gestation
is eight- to ninefold higher in twin than in singleton
gestations4. Several interventions have been proposed
to reduce the rate of preterm birth in twin gestations,
such as bed rest16, prophylactic tocolysis17, nutritional
advice18, administration of 17α-hydroxyprogesterone
caproate19, vaginal progesterone19, cerclage20 and
cervical pessary21,22. Unfortunately, these interventions
have not been shown to reduce the risk of preterm birth
in unselected twin gestations.
A short cervix, traditionally defined as a transvagi-
nal sonographic cervical length (CL) ≤ 25 mm in the
mid-trimester of pregnancy, is an important risk fac-
tor for spontaneous preterm birth and has emerged as
one of the strongest and most consistent predictors of
preterm birth in asymptomatic women with singleton23–29
or twin gestations30–43. Currently, there is compelling
evidence that administration of vaginal progesterone to
asymptomatic women with a singleton gestation and a
sonographic short cervix decreases the risk of preterm
birth and neonatal morbidity and mortality44–46. The
efficacy of vaginal progesterone in women with a twin
gestation and a short cervix has been less studied.
A meta-analysis of individual patient data (IPD)
published in 2012 reported on the efficacy of vaginal
progesterone in preventing preterm birth and neonatal
morbidity and mortality in asymptomatic women with a
twin gestation and a CL ≤ 25 mm in the mid-trimester47.
A total of 52 women (104 fetuses/infants) from three
randomized controlled trials (RCTs) were included in the
study. The use of vaginal progesterone was associated
with a significant 44% reduction in the risk of composite
neonatal morbidity and mortality (relative risk (RR), 0.56
(95% CI, 0.30–0.97)) and a 30% non-significant reduc-
tion in the risk of preterm birth < 33 weeks’ gestation
(RR, 0.70 (95% CI, 0.34–1.44)). Since that time, addi-
tional RCTs evaluating the use of vaginal progesterone
in twin gestations have been published. Therefore, a
reassessment of the efficacy of this intervention in women
with a twin gestation and a short cervix is justified.
The objective of this study was to update the previous
IPD meta-analysis on the efficacy of vaginal progesterone
in asymptomatic women with a twin gestation and a
sonographic CL ≤ 25 mm in the mid-trimester for the
prevention of preterm birth and neonatal morbidity and
mortality.
METHODS
The study was conducted according to a prospectively
prepared protocol and reported in accordance with the
Preferred Reporting Items for Systematic reviews and
Meta-Analyses statement48. The review was registered
with PROSPERO (number CRD42016039682).
Data sources and searches
We searched MEDLINE, EMBASE, POPLINE, CINAHL
and LILACS (all from inception to 31 December 2016),
the Cochrane Central Register of Controlled Trials and
Research Registers of ongoing trials using a combination
of keywords and text words related to ‘progesterone’,
‘preterm birth’, ‘randomized controlled trial’ and ‘twin
gestation’. Google Scholar, proceedings of congresses
on obstetrics, maternal-fetal medicine and ultrasound in
obstetrics, reference lists of identified studies, previously
published systematic reviews and review articles were also
searched. Experts in the field were contacted to identify
further studies. No language restrictions were applied.
Study selection
RCTs in which asymptomatic women with a twin
gestation and a sonographic short cervix (CL ≤ 25 mm)
in the mid-trimester were allocated randomly to receive
vaginal progesterone or placebo/no treatment for the
prevention of preterm birth and/or adverse perinatal
outcomes were eligible for inclusion in the review. Trials
were included if the primary aim of the study was to
prevent preterm birth in women with a twin gestation and
a short cervix, or to prevent preterm birth in women with
an unselected twin gestation but for whom outcomes were
available in those with a prerandomization CL ≤ 25 mm.
We excluded quasirandomized trials, trials that evaluated
Published 2017. This article is a U.S. Government work and is in the public domain in the USA. Ultrasound Obstet Gynecol 2017; 49: 303–314.
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vaginal progesterone in women with preterm labor,
arrested preterm labor (as maintenance tocolysis), preterm
rupture of membranes or second-trimester bleeding, trials
that assessed vaginal progesterone in the first trimester
only to prevent miscarriage and studies that did not report
clinical outcomes. Studies published only as abstracts were
excluded if additional information on methodological
issues and results could not be obtained.
All of the potentially relevant studies were retrieved
and reviewed independently by two authors to determine
inclusion. Disagreements were resolved by discussion
amongst the reviewers.
Data collection
The corresponding author of each eligible trial was
contacted and asked to provide anonymized data (without
identifiers) about baseline characteristics and outcomes
for every randomly assigned patient, as well as data
on study characteristics and details of interventions and
co-interventions. All initial communications with authors
were based on a template explaining the study and the
data required. Data provided by the investigators were
merged into a master database specifically constructed for
the review. Data were checked for missing information,
errors and inconsistencies by cross-referencing with the
publications of the original trials. Quality and integrity of
the randomization processes were assessed by reviewing
the chronological randomization sequence and pattern
of assignment, as well as the balance of baseline
characteristics across treatment groups. Inconsistencies
or missing data were discussed with the authors and
corrections were made when deemed necessary.
Informed consent was provided by the patients upon
enrollment in each of the original trials. In the present
study, the data were not used for any purposes other than
those of the original trial and no new data were collected.
Therefore, informed consent specifically for this project
was not considered necessary. This study was exempted
from review by the Human Investigation Committee
Administration Office of Wayne State University.
Outcome measures
The primary outcome measure was preterm birth
< 33 weeks’ gestation. Secondary outcome measures
included: preterm birth <37, < 36, < 35, <34, < 32,
< 30 and<28 weeks’ gestation; spontaneous preterm
birth < 33 and< 34 weeks’ gestation; respiratory distress
syndrome (RDS); necrotizing enterocolitis; intraventric-
ular hemorrhage; proven neonatal sepsis; retinopathy
of prematurity; fetal death; neonatal death; perinatal
death; a composite outcome of neonatal morbidity
and mortality (defined as the occurrence of any of the
following events: RDS, intraventricular hemorrhage,
necrotizing enterocolitis, proven neonatal sepsis or neona-
tal death); birth weight<1500 g and< 2500 g; admission
to the neonatal intensive care unit; use of mechanical
ventilation; and long-term neurodevelopmental outcomes
(suspected or diagnosed developmental delay, cerebral
palsy, intellectual disabilities, vision impairment, hearing
loss, cognitive and behavioral impairments and motor,
communication and learning disorders at any age in
childhood).
Assessment of risk of bias
The risk of bias in each included trial was assessed
independently by two authors using the criteria outlined
in the Cochrane Handbook for Systematic Reviews of
Interventions49. This tool assesses seven domains related
to risk of bias (random sequence generation, allocation
concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome
data, selective reporting and other bias) and categorizes
studies by low, unclear or high risk of bias in each
domain. Disagreements in risk of bias assessment were
resolved through consensus.
Statistical analysis
We included all randomized women and their fetuses/
infants and performed all analyses on an intention-to-treat
basis. For outcomes dealing with gestational age at
delivery, the unit of analysis was the pregnancy,
whereas for perinatal outcomes, the unit of analysis was
the fetus/neonate. IPD were combined in a two-stage
approach in which outcomes were analyzed in the original
trial and then summary statistics were generated using
standard summary data meta-analysis techniques to give
an overall measure of effect (pooled RR with 95%
CI)50. Heterogeneity of the results among studies was
tested51 with the quantity I2. We pooled results from
individual studies using a fixed-effect model if substantial
statistical heterogeneity was not present (< 50%). If I2
values were ≥ 50%, a random-effects model was used to
pool data across studies. For adverse perinatal outcomes,
we estimated pooled RRs using analytical methods that
assumed independence between neonates. However, to
avoid incorrect conclusions due to the non-independence
of newborns from twin gestations, we also used a
generalized linear model with generalized estimating
equations to estimate parameters while controlling for
cluster correlations52–54. The number needed to treat
for benefit or harm, with a 95% CI, was calculated for
outcomes for which there was a statistically significant
reduction or increase in risk difference based on control
event rates in the trials55.
Subgroup analyses were performed to evaluate the effect
of vaginal progesterone according to CL (<10, 10–20
and 21–25 mm), daily dose of vaginal progesterone (100,
200 and 400 mg) and obstetric history (no previous
spontaneous preterm birth < 37 weeks’ gestation and at
least one previous spontaneous preterm birth <37 weeks’
gestation). A test for interaction between the treatment
and subgroups was performed to examine whether
treatment effects differed among subgroups56–58. An
interaction P-value ≥ 0.05 was considered to indicate
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that the effect of treatment did not differ significantly
among subgroups. We planned to carry out sensitivity
analyses to explore the effect of trial quality assessed by
allocation concealment and random sequence generation
(considering selection bias) and blinding (considering
performance and detection biases), with studies rated as
‘high risk of bias’ or ‘unclear risk of bias’ for these domains
being excluded from the analyses in order to assess
whether this made any difference to the overall result.
Subgroup and sensitivity analyses were only performed
for the primary outcome of preterm birth < 33 weeks’
gestation and for the secondary outcome of neonatal
death. We also planned to explore potential sources of
heterogeneity and to assess publication and related biases
if at least 10 studies were included in a meta-analysis,
but these analyses were not undertaken due to the limited
number of trials included in the review.
Quality of evidence
We used the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach, as
outlined in the GRADE Handbook59, to assess the quality
of evidence for primary and secondary outcome measures.
We considered evidence from RCTs as high quality but
downgraded the evidence by one level for serious (or
two levels for very serious) limitations based upon the
following: design (risk of bias), consistency across studies,
directness of the evidence, precision of estimates and
presence of publication bias. The GRADEpro Guideline
Development Tool60 was used to import data from
Review Manager in order to create a ‘Summary of
findings’ table to report the quality of the evidence.
The GRADE approach results in an assessment of the
quality of a body of evidence in one of four grades:
(i) high: we are very confident that the true effect lies
close to that of the estimate of the effect; (ii) moderate:
we are moderately confident in the effect estimate, the
true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially
different; (iii) low: our confidence in the effect estimate
is limited, the true effect may be substantially different
from the estimate of the effect; and (iv) very low: we have
very little confidence in the effect estimate, the true effect
is likely to be substantially different from the estimate
of effect.
Records identified through
database search (n = 281)
Additional records identified
through other sources (n = 0)
Records after duplicates removed (n = 213)
Records screened (n = 213) Records excluded (n = 204)
Full-text articles assessed
for eligibility (n = 9)
Studies included in qualitative synthesis (n = 6)
Full-text articles excluded (n = 3)
• CL not measured or collected
before randomization (n = 2)
•  No data on women with CL
≤ 25 mm at randomization (n = 1)
Studies included in meta-analysis (n = 6)
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Figure 1 Study selection process. CL, cervical length.
We performed all statistical analyses using Review
Manager (RevMan, version 5.3.5; The Nordic Cochrane
Centre, Copenhagen, Denmark) and SAS version 9.2 (SAS
Institute, Cary, NC, USA) software.
RESULTS
Selection, characteristics and risk of bias of studies
Figure 1 summarizes the process of identification and
selection of studies. A total of 213 records were identi-
fied by the searches, of which nine were retrieved for
full-text review. Three studies, which evaluated vagi-
nal progesterone in unselected twin gestations61,62 or
pregnancies conceived by in-vitro fertilization or intracy-
toplasmic sperm injection63, were excluded because CL
was not measured or collected before randomization or
there were no data for women with a CL ≤ 25 mm at ran-
domization. Six studies, including a total of 303 women
(606 fetuses/infants) with a CL ≤ 25 mm, met the inclu-
sion criteria64–69; 159 women were assigned to vaginal
progesterone and 144 to placebo/no treatment. Minimal
differences were noted in baseline maternal character-
istics between the vaginal progesterone and placebo/no
treatment groups (Table 1).
Table 1 Baseline characteristics of pooled women
Characteristic Vaginal progesterone (n = 159) Placebo/no treatment (n = 144)
Maternal age (years) 27 (25–30) 28 (25–31)
Body mass index (kg/m2) 22.4 (21.2–25.7)* 22.9 (21.0–25.4)†
Smoker 3 (1.9) 3 (2.1)
Previous spontaneous PTB 28 (17.6) 28 (19.4)
Monochorionic pregnancy 8 (5.0) 6 (4.2)
GA at randomization (weeks) 21.7 (20.6–23.1) 22.1 (21.1–23.3)
CL at randomization (mm) 22 (20–23) 22 (20–23)
CL ≤ 20 mm at randomization 49 (30.8) 47 (32.6)
Data are given as median (interquartile range) or n (%). *n = 41. †n = 36. CL, cervical length; GA, gestational age; PTB, preterm birth.
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The individual characteristics of the studies included
in the meta-analysis are shown in Table 2. Five stud-
ies were double-blind, placebo-controlled trials64–68.
The remaining study compared vaginal progesterone
with no treatment69. Three studies were performed in
low/middle-income countries65,68,69, two in high-income
countries66,67 and one in both low/middle- and
high-income countries64. Two trials were specifically
designed to evaluate the use of vaginal progesterone in
women with a twin gestation and a sonographic short
cervix (CL ≤ 15 mm64 and CL between 20 and 25 mm69).
The remaining four studies tested the effect of vaginal
progesterone in women with unselected twin gestations
and their authors provided data relevant to women
with a CL ≤ 25 mm before randomization65–68. The trial
that assessed vaginal progesterone in women with a CL
between 20 and 25 mm69 provided data for 224 moth-
ers and their 448 fetuses/infants. The other five studies
provided data for 79 women and 158 fetuses/infants.
Three studies used vaginal progesterone 200 mg/day
(capsule64, pessary66 or ovule68), one used vaginal pro-
gesterone suppositories 100 mg/day65, one used vaginal
progesterone suppositories 400 mg/day69 and the remain-
ing study used vaginal progesterone suppositories 200
or 400 mg/day67. Treatment was started between 20 and
24 weeks’ gestation in five trials64–67,69, and between 18
and 21 weeks’ gestation in the remaining trial68. Five stud-
ies reported that participants received medication from
the time of enrollment until ∼34 weeks’ gestation64–68,
and one study reported medication from enrollment until
37 weeks’ gestation69. Two trials included only women
with a dichorionic twin gestation67,69. Major fetal abnor-
mality, cervical cerclage in place or planned, allergy
to progesterone and hepatic dysfunction were reported
as exclusion criteria in most studies. The primary out-
come measure was preterm birth < 34 weeks’ gestation
in two trials66,69, preterm birth < 37 weeks’ gestation in
two trials65,67, spontaneous preterm birth < 34 weeks’
gestation in one trial64 and mean gestational age at deliv-
ery in the remaining study68. The study by El-Refaie
et al.69 did not collect data for some neonatal mor-
bidities, such as necrotizing enterocolitis, intraventricular
hemorrhage, proven neonatal sepsis and retinopathy of
prematurity.
The risk of bias in each included study is summarized in
Figure 2. All studies had adequate generation of allocation
sequence and concealment of allocation, and appeared
to be free of selective outcome reporting and other
sources of bias. Five studies were considered to be at
low risk of selection, performance, detection, attrition
and reporting biases64–68. The study by El-Refaie et al.69
had a high risk of performance and detection biases
because patients, clinical staff and outcome assessors were
not blinded to the allocated interventions. In addition,
this trial was judged to be at unclear risk of attrition
bias because the number of losses to follow-up was
not balanced across study groups (7.2% in the vaginal
progesterone group and 13.6% in the no treatment
group).
Effect of vaginal progesterone on preterm birth
Women allocated to receive vaginal progesterone had
a significantly lower risk of preterm birth <33 weeks’
gestation (31.4% vs 43.1%; RR, 0.69 (95% CI, 0.51–
0.93); P = 0.01; I2 = 0%; six studies, 303 women;
moderate-quality evidence) compared with those allo-
cated to placebo/no treatment (Figure 3). In addi-
tion, vaginal progesterone was associated with a
significant reduction in the risk of preterm birth
< 35 weeks’ gestation (RR, 0.83 (95% CI, 0.69–0.99);
moderate-quality evidence), < 34 weeks’ gestation (RR,
0.71 (95% CI, 0.56–0.91); moderate-quality evidence),
< 32 weeks’ gestation (RR, 0.51 (95% CI, 0.34–0.77);
moderate-quality evidence), < 30 weeks’ gestation (RR,
0.47 (95% CI, 0.25–0.86); moderate-quality evidence),
and spontaneous preterm birth at< 33 weeks’ gestation
(RR, 0.67 (95% CI, 0.48–0.93); moderate-quality evi-
dence) and<34 weeks’ gestation (RR, 0.71 (95% CI,
0.54–0.93); moderate-quality evidence) (Table 3). The
number needed to treat to prevent one case of preterm
birth occurring at < 30 to< 35 gestational weeks var-
ied from 6 to 12. There were no significant differences
between the study groups in the risk of preterm birth
< 37 weeks’ (moderate-quality evidence), <36 weeks’
(moderate-quality evidence) and< 28 weeks’ (low-quality
evidence) gestation.
Effect of vaginal progesterone on adverse perinatal
outcomes
Infants whose mothers received vaginal progesterone
had a significantly lower risk of neonatal death
(RR, 0.53 (95% CI, 0.35–0.81); moderate-quality evi-
dence), perinatal death (RR, 0.58 (95% CI, 0.39–0.84);
moderate-quality evidence), RDS (RR, 0.70 (95%
CI, 0.56–0.89); moderate-quality evidence), compos-
ite neonatal morbidity and mortality (RR, 0.61
(95% CI, 0.34–0.98); moderate-quality evidence), birth
weight< 1500 g (RR, 0.53 (95% CI, 0.35–0.80);
moderate-quality evidence) and use of mechanical venti-
lation (RR, 0.54 (95% CI, 0.36–0.81); moderate-quality
evidence) (Table 4). The number needed to treat to pre-
vent one case of these adverse perinatal outcomes varied
from 6 to 8. There was no evidence of an effect of vagi-
nal progesterone on necrotizing enterocolitis (low-quality
evidence), intraventricular hemorrhage (low-quality evi-
dence), proven neonatal sepsis (low-quality evidence),
retinopathy of prematurity (low-quality evidence), fetal
death (very low-quality evidence), birth weight< 2500 g
(moderate-quality evidence) and admission to the neona-
tal intensive care unit (moderate-quality evidence).
Subgroup and sensitivity analyses
Subgroup analyses of the effect of vaginal progesterone on
preterm birth < 33 weeks’ gestation and neonatal death,
according to CL, daily dose of vaginal progesterone
and obstetric history, are shown in Table 5. There
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was no evidence that women in any one of the
prespecified subgroups benefited more or less from the
use of vaginal progesterone than those in any other
subgroup (all, interaction P-value ≥ 0.40). Nonetheless,
vaginal progesterone was associated with a statistically
significant reduction in the risk of preterm birth
< 33 weeks’ gestation and neonatal death in women
with a CL between 10 and 20 mm (RR, 0.44 (95% CI,
0.22–0.87) and 0.20 (95% CI, 0.05–0.86), respectively)
and women who were administered 400 mg of daily
vaginal progesterone (RR, 0.66 (95% CI, 0.46–0.95)
and 0.42 (95% CI, 0.23–0.76), respectively). Moreover,
vaginal progesterone significantly decreased the risk of
neonatal death in women with a CL between 21 and
25 mm (RR, 0.57 (95% CI, 0.36–0.90)) and women with
no previous spontaneous preterm birth (RR, 0.58 (95%
CI, 0.36–0.93)).
When the sensitivity analysis was restricted to the five
trials with adequate blinding of patients, clinical staff and
outcome assessors64–68, the effect of vaginal progesterone
on the reduction in the risk of preterm birth <33 weeks’
gestation and neonatal death was non-significant (RR,
0.77 (95% CI, 0.48–1.24) and 0.56 (95% CI, 0.21–1.48),
respectively). However, it should be noted that the
sensitivity analyses did not substantially change the
magnitude and direction of effect sizes obtained in the
overall analyses. Sensitivity analyses based on allocation
concealment and random sequence generation were not
performed because there were no trials at unclear or high
risk of bias for these domains.
Effect of vaginal progesterone on long-term
neurodevelopmental outcomes
No study has reported the effects of vaginal progesterone
on long-term neurodevelopmental outcomes in twin ges-
tations with a short cervix. Thus far, two trials have
reported the effects of prenatal exposure to vaginal pro-
gesterone on long-term neurodevelopmental outcomes in
unselected twin gestations70,71. In 2015, a follow-up study
of one of the excluded trials61 reported that there was no
significant difference in developmental delay (assessed
using the Child Development Inventory tool) between
twins exposed to either vaginal progesterone (42/140) or
placebo (65/184) at a mean age of 55.5 months (odds ratio
(OR), 0.87 (95% CI, 0.46–1.63))70. Recently, one of the
studies included in the review66 reported on the devel-
opmental performance of children exposed prenatally to
vaginal progesterone (n = 225) or placebo (n = 212), at
a mean age of 57 months71. The developmental perfor-
mance was evaluated by the parent-completed Ages and
Stages Questionnaire (ASQ) screening tool. Overall, mean
ASQ total scores were significantly higher in the vagi-
nal progesterone-exposed group (269 ± 28) than in the
placebo-exposed group (262 ± 31) (P = 0.03), although
there was no statistically significant difference in the
risk of low ASQ score (< 10th percentile) between the
study groups (OR, 0.47 (95% CI, 0.21–1.06)). A sub-
group analysis showed that dichorionic twins who were
0.05 0.1 0.2 0.3 0.5 1 2 3 5 10
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Figure 3 Forest plot of the effect of vaginal progesterone on the risk of preterm birth < 33 weeks’ gestation. CI, confidence interval.
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Table 3 Effect of vaginal progesterone on the risk of preterm birth
Events (n)/Total (N)
Outcome
Trials
(nrefs)
Vaginal
progesterone
Placebo/no
treatment
Pooled RR
(95% CI)
I2
(%)
NNT
(95% CI)
Preterm birth < 37 weeks 664–69 137/159 131/144 0.94 (0.86–1.02) 0 —
Preterm birth < 36 weeks 664–69 112/159 110/144 0.92 (0.80–1.05) 0 —
Preterm birth < 35 weeks 664–69 90/159 98/144 0.83 (0.69–0.99) 0 9 (5–147)
Preterm birth < 34 weeks 664–69 63/159 78/144 0.71 (0.56–0.91) 0 6 (4–21)
Preterm birth < 32 weeks 664–69 29/159 46/144 0.51 (0.34–0.77) 0 6 (5–14)
Preterm birth < 30 weeks 664–69 14/159 22/144 0.47 (0.25–0.86) 0 12 (9–47)
Preterm birth < 28 weeks 664–69 9/159 12/144 0.51 (0.24–1.08) 0 —
Spontaneous preterm birth < 33 weeks 664–69 42/159 54/144 0.67 (0.48–0.93) 0 8 (5–38)
Spontaneous preterm birth < 34 weeks 664–69 55/159 69/144 0.71 (0.54–0.93) 0 7 (5–30)
CI, confidence interval; NNT, number needed to treat; refs, reference numbers; RR, relative risk.
Table 4 Effect of vaginal progesterone on the risk of adverse perinatal outcomes
Pooled RR (95% CI)
Events (n)/Total (N)
Outcome
Trials
(nrefs)
Vaginal
progesterone
Placebo/no
treatment
Assuming
independence
between twins
Adjustment
for non-
independence
between twins
I2
(%)
NNT
(95% CI)
Respiratory distress syndrome 664–69 102/311 131/280 0.67 (0.55–0.82) 0.70 (0.56–0.89) 0 6 (4–16)
Necrotizing enterocolitis 564–68 1/82 0/68 1.00 (0.04–22.43) 1.07 (0.05–22.25) NA —
Intraventricular hemorrhage 564–68 2/80 2/68 0.93 (0.15–5.75) 1.47 (0.22–9.63) 0 —
Proven neonatal sepsis 564–68 4/80 7/68 0.44 (0.13–1.46) 0.59 (0.18–1.93) 0 —
Retinopathy of prematurity 564–68 1/80 1/68 0.42 (0.07–2.56) 0.45 (0.08–2.59) 17 —
Fetal death 664–69 9/318 9/288 0.57 (0.23–1.42) 0.68 (0.26–1.84) 0 —
Neonatal death 664–69 34/318 63/288 0.50 (0.34–0.71) 0.53 (0.35–0.81) 25 8 (5–19)
Perinatal death 664–69 43/318 72/288 0.51 (0.36–0.70) 0.58 (0.39–0.84) 24 7 (5–20)
Composite neonatal
morbidity/mortality*
564–68 23/84 28/70 0.57 (0.36–0.93) 0.61 (0.34–0.98) 0 6 (3–109)
Birth weight< 1500 g 664–69 48/315 73/280 0.52 (0.38–0.72) 0.53 (0.35–0.80) 17 7 (5–17)
Birth weight< 2500 g 664–69 244/315 223/280 0.97 (0.89–1.06) 0.99 (0.89–1.10) 0 —
Admission to the NICU 664–69 211/315 209/282 0.92 (0.83–1.02) 0.95 (0.84–1.08) 0 —
Mechanical ventilation 664–69 49/311 76/280 0.52 (0.37–0.71) 0.54 (0.36–0.81) 0 7 (5–17)
*Occurrence of any of the following events: respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, proven
neonatal sepsis or neonatal death. CI, confidence interval; NA, not applicable; NICU, neonatal intensive care unit; NNT, number needed to
treat; refs, reference numbers; RR, relative risk.
exposed prenatally to vaginal progesterone had a signif-
icantly lower risk of having a low total ASQ score than
those who were exposed to placebo (OR, 0.34 (95% CI,
0.14–0.86)).
DISCUSSION
Principal findings
The main finding in this updated IPD meta-analysis
is that the administration of vaginal progesterone
to asymptomatic women with a twin gestation and
a mid-trimester sonographic short cervix significantly
reduces the risk of preterm birth <33 weeks’ gestation
(primary outcome) by 31% and neonatal death by 47%.
In addition, patients who received vaginal progesterone
had a significantly decreased risk of preterm birth < 35,
< 34, < 32 and< 30 weeks, spontaneous preterm birth
< 33 and< 34 weeks, perinatal death, composite neonatal
morbidity and mortality, RDS, birth weight< 1500 g and
use of mechanical ventilation. Moreover, evidence from
two trials that assessed vaginal progesterone in unselected
twin gestations showed that there were no significant
differences in the risk of neurodevelopmental disability at
4–5 years of age between children exposed prenatally to
vaginal progesterone and those exposed to placebo.
Quality of the evidence
Evidence for most critical outcomes assessed with GRADE
methodology was considered to be of moderate quality
(Table S1). We downgraded the evidence from high
quality to moderate quality because most of the pooled
effect was provided by one study with moderate risk of
bias. A judgment of moderate quality means that we have
some confidence that our results approach the true impact
of vaginal progesterone on preterm birth and adverse
neonatal outcomes in twin gestations with a short cervix;
at the same time, we acknowledge that future trials may
change these results.
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Table 5 Subgroup analyses of the effect of vaginal progesterone on preterm birth < 33 weeks’ gestation and neonatal death
Preterm birth < 33 weeks’ gestation Neonatal death
Subgroup n Pooled RR (95% CI) Interaction P-value n Pooled RR (95% CI)* Interaction P-value
Cervical length 0.40 0.40
< 10 mm 14 0.74 (0.37–1.49) 28 0.67 (0.12–3.70)
10–20 mm 82 0.44 (0.22–0.87) 164 0.20 (0.05–0.86)
21–25 mm 207 0.74 (0.51–1.06) 414 0.57 (0.36–0.90)
Daily dose of vaginal progesterone 0.77 0.60
100 mg 7 0.40 (0.04–3.74) 14 0.09 (0.00–3.59)
200 mg 69 0.79 (0.48–1.30) 138 0.66 (0.15–2.86)
400 mg 227 0.66 (0.46–0.95) 454 0.42 (0.23–0.76)
Obstetric history 0.40 0.62
No previous preterm birth 247 0.72 (0.52–1.01) 494 0.58 (0.36–0.93)
≥ 1 previous preterm birth 56 0.50 (0.22–1.11) 112 0.45 (0.18–1.10)
*Adjusted for non-independence between twins. CI, confidence interval; RR, relative risk.
Subgroup analyses
We evaluated several clinically important subgroups based
on CL, daily dose of vaginal progesterone and history
of spontaneous preterm birth. Overall, subgroup analyses
indicated that the beneficial effects of vaginal progesterone
did not differ significantly across patient groups, as
the interaction tests for subgroup differences were
non-significant. Patients with a CL between 10 and 20 mm
or those who received vaginal progesterone 400 mg/day
seemed to have a greater-than-average reduction in
the risk of preterm birth < 33 weeks’ gestation and
neonatal death. However, analyses of categories such
as CL< 10 mm, daily dose of vaginal progesterone of
100 or 200 mg and history of spontaneous preterm birth
were based on small numbers of women, reflecting the
pattern of recruitment to the original trials, in which most
women had a CL between 10 and 25 mm, used vaginal
progesterone 400 mg/day and did not have a history of
spontaneous preterm birth. As a result, our analysis was
limited in its power to estimate effects within those groups
of patients. Thus, although prespecified and clinically
interesting, these subgroup analyses should be interpreted
with caution.
Lack of long-term adverse neurodevelopmental
outcomes in twins exposed to vaginal progesterone
during pregnancy
Current evidence suggests that in-utero exposure to
vaginal progesterone, administered in twin gestations
for the prevention of preterm birth, has no detrimental
effects on long-term neurodevelopmental outcomes. A
total of 761 surviving children who participated in
two placebo-controlled trials of vaginal progesterone to
prevent preterm birth in unselected twin gestations61,66
were evaluated at a mean age of ∼56 months for
neurodevelopmental outcomes70,71. Both studies reported
no significant differences in the risk of developmental
delay70 or suspected developmental delay71 between
children whose mothers received vaginal progesterone
and those whose mothers received placebo. It should
be noted that vaginal progesterone had no effect on
gestational age at delivery in both trials, which allowed
the assessment of the direct effect of vaginal progesterone
on childhood neurodevelopmental outcomes independent
of any effect of vaginal progesterone on preterm birth.
Interestingly, a subgroup analysis of one of these studies70
found that dichorionic twins who were exposed prenatally
to progesterone had a significantly reduced risk of a
low total ASQ score, a higher total mean ASQ score
and higher mean ASQ scores in communication, gross
motor skills and personal/social skills in comparison with
dichorionic twins who were exposed to placebo. These
findings suggest a potential long-term benefit related to
prenatal exposure to vaginal progesterone, which would
not be surprising because there is some evidence indicating
that progesterone could act as a neuroprotectant for
brain disorders, mainly traumatic brain injury72. Thereby,
a direct beneficial effect of vaginal progesterone on
childhood neurodevelopment would be plausible. This
issue deserves further investigation.
Lack of long-term adverse health outcomes in twins
exposed to vaginal progesterone during pregnancy
With regard to the effects of the prenatal exposure
to vaginal progesterone on childhood health outcomes
in twins, the follow-up study by McNamara et al.70
reported that there were no significant differences between
vaginal progesterone-exposed and placebo-exposed twins
with respect to death, congenital malformations, growth,
health service utilization and global health status at
3–6 years of age. The follow-up study by Vedel
et al.71 reported that the rates of diagnoses related
to 10 organ systems, the median number of hospital
admissions and the median length of hospital stay did
not differ significantly between the vaginal progesterone-
and placebo-exposed twins up to 8 years of age.
Notwithstanding, in subgroup analyses restricted to
dichorionic twins and diagnoses made solely during
hospital admission, the investigators found that diagnoses
related to structural and functional abnormalities of the
heart were significantly more frequent among children
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who were exposed prenatally to vaginal progesterone.
However, these differences became non-significant after
Bonferroni adjustment for multiple comparisons. In
conclusion, second- and third-trimester exposure to
vaginal progesterone does not seem to have harmful effects
on the childhood health of twins.
Lack of adverse maternal events
In our previous IPD meta-analysis47, in which all included
studies used vaginal progesterone 90–200 mg/day, the
rates of maternal adverse effects, such as vaginal
discharge, vaginal pruritus and discontinuation of
treatment because of adverse effects, were similar between
the vaginal progesterone and placebo groups. In 2013, the
three-armed trial by Serra et al.67 comparing placebo with
two different daily doses of vaginal progesterone (200
and 400 mg) reported a dose-dependent, non-significant
trend towards a higher rate of intrahepatic cholestasis of
pregnancy (0% in the placebo group, 1% in the group
receiving 200 mg and 5% in the group receiving 400 mg).
Nonetheless, the larger study by El-Refaie et al.69 reported
that there was no significant difference in the rate of
intrahepatic cholestasis of pregnancy between the group
using 400 mg of daily vaginal progesterone (1%) and the
no treatment group (0%). Moreover, this study found that
the rates of vaginal pruritus, vaginal discharge, headache,
skin rash and gastrointestinal symptoms did not differ
significantly between the study groups. Thus, it appears
that a 400-mg daily dose of vaginal progesterone is not
associated with an increased risk of adverse maternal
effects as compared with a 200-mg daily dose of vaginal
progesterone or placebo/no treatment.
Strengths and limitations
The main strengths of our meta-analysis include: (i) the
use of patient-level data, which offer several advantages
over study-level analysis, including the ability to use
more appropriate statistical methods not always feasible
using study-level analysis, define outcome measures
consistently across studies, investigate subgroups in which
treatment may be either more or less effective, address
questions that have not been satisfactorily resolved by
individual trials, minimize publication and reporting
biases and adjust for prognostic variables that may
have confounded the original treatment comparisons;
(ii) the baseline balance in prognostic factors between
the two study groups, which reduces the possibility
of causing bias in the intervention effect estimates;
(iii) the absence of substantial heterogeneity in most of
the meta-analyses performed; indeed, all meta-analyses on
the effect of vaginal progesterone on preterm birth had no
observed heterogeneity (I2 = 0%), whereas the majority
of meta-analyses regarding adverse perinatal outcomes
had low heterogeneity or no heterogeneity; and (iv) the
sensitivity analyses restricted to trials at low risk of bias
that were consistent with (and thus supportive of) the
overall findings.
Some potential limitations must also be considered.
First, only two trials were specifically designed to assess
the efficacy of vaginal progesterone in women with a twin
gestation and a sonographic short cervix. Second, 74%
of the total sample size of the IPD meta-analysis was pro-
vided by one study69, which included women with a CL
between 20 and 25 mm and was not placebo-controlled.
However, it should be highlighted that assessment
and measurement of most outcomes included in our
review are considered objective in nature, and therefore
not likely to be influenced by lack of blinding49. It
is noteworthy that estimates of pooled RRs obtained
after excluding this study were not significantly different
from those obtained in the overall analyses. Moreover,
the significant 39% reduction in the risk of composite
neonatal morbidity and mortality associated with vaginal
progesterone administration was obtained without
including data from the study by El-Refaie et al.69 in the
meta-analysis. Third, the larger study69 did not collect
information about several neonatal morbidities, such as
necrotizing enterocolitis, intraventricular hemorrhage,
proven neonatal sepsis and retinopathy of prematurity.
Finally, some subgroup analyses included a small number
of patients, which limits the statistical power to estimate
the effects within these subgroups.
Implications for practice and research
This updated IPD meta-analysis indicates that vaginal
progesterone reduces the risk of preterm birth and
neonatal morbidity and mortality in patients with a
twin gestation and a sonographic short cervix, without
any deleterious effects on childhood neurodevelopment.
Although the results of our meta-analysis appear
promising, further research is required before conclusive
advice can be provided with regard to the benefits
of using vaginal progesterone in women with a twin
gestation and a short cervix. Evidence from this updated
IPD meta-analysis and three ongoing RCTs comparing
vaginal progesterone with placebo (NCT02697331 and
NCT02518594) or no treatment (NCT02329535) in
∼750 women with a twin gestation and a sonographic
short cervix will help to determine whether vaginal
progesterone can be recommended to these patients
with the aim of preventing preterm birth and improving
perinatal outcomes.
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